Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

BACKGROUND: Congenital haemophilia A (HA) is a rare, inherited, life-long bleeding disorder characterised by prolonged or spontaneous bleeding due to the lack of clotting factor VIII (FVIII) in the body. Treatment for HA involves FVIII replacement therapy and poses great economic burden to National...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzoni, Valentina, Triulzi, Isotta, Turchetti, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090904/
https://www.ncbi.nlm.nih.gov/pubmed/30071878
http://dx.doi.org/10.1186/s12913-018-3398-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090904/
https://www.ncbi.nlm.nih.gov/pubmed/30071878
http://dx.doi.org/10.1186/s12913-018-3398-x

Ejemplares similares